# Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

> **NCT00751621** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 40 (actual)

## Conditions studied

- Primary Immunodeficiency (PID)

## Interventions

- **BIOLOGICAL:** IgPro20

## Key facts

- **NCT ID:** NCT00751621
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751621, "Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00751621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*